Articles related to Pharmacy (Community)

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

Two phase 3 trials found upadacitinib increased scalp, eyebrow, and eyelash regrowth in adolescents and adults with severe alopecia areata. Longer-term safety, durability, and regulatory review remain important considerations.

The FDA classified a voluntary nationwide recall involving nearly 12 million cartons of Rohto Cooling Eye Drops after a lack of assurance of sterility was identified. The action was designated a Class II recall, indicating medically reversible risks or a remote probability of serious harm.

In an observational target trial emulation of patients with atrial fibrillation and mitral stenosis, DOACs were associated with higher 1-year stroke risk than warfarin. Bleeding and all-cause mortality risks did not differ between groups.

Benzodiazepine use among U.S. adults aged 65 years and older declined before 2020 but remained largely unchanged through 2024. Long-term use persisted in roughly one-third of users, with smaller reductions among adults aged 75 years and older.